Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo tested in fight against spreading prostate cancer

NCT ID NCT07140900

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and side effects of a new drug called xaluritamig when given alongside standard hormone-blocking treatments. It is for men whose prostate cancer has spread and is still responding to hormone therapy. The main goal is to see if the combination is safe and tolerable, while also checking for early signs that it might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cabrini Hospital

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Calvary Mater Newcastle Hospital

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Centre Hospitalier Universitaire Vaudois

    RECRUITING

    Lausanne, 1011, Switzerland

  • Chris OBrien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Kantonsspital Graubuenden

    RECRUITING

    Chur, 7000, Switzerland

  • Kantonsspital Sankt Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)